lupin_pharma_logo

Lupin completes acquisition of US-based Gavis Pharmaceuticals

pharmafile | March 10, 2016 | News story | Research and Development, Sales and Marketing FDA, Gavis, Lupin, acquisition, generics 

Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal worth $880 million.

As reported previously, the deal will see Lupin enhance its presence in the US generic market, with access to Gavis’ 62 generic drugs, which the firm has already filed to the FDA for approval.

72% of these ANDA filings pending approval requests represent niche dosage forms with 18 Para IVs and eight FTFs products. The existing pending approvals of Gavis address a market of over $9 billion.

Advertisement

Vinita Gupta, chief executive officer at Lupin, comments: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as speciality pipeline.”

Sean Murray

Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …

The Gateway to Local Adoption Series

Latest content